They use the Internet, the application of innovative technology and the assistance of licensed securities brokers when appropriate to provide a broad universe of accredited and institutional investors with efficient access to private company stock investment opportunities and to take friction out of the transaction process.

FORBES: The Case For Private Company Stock Marketplaces

This morning, Roche announced that the Food and Drug Administration refused to consider the application for the TDM-1 breast cancer drug based on technology that it licensed from Immunogen, a Waltham, Mass. biotechnology company.

FORBES: Bad News For Immunogen